Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

dreaMS

Financiado

Cerrado

Digital biomarkers and treatment personalisation in multiple sclerosis

Multiple Sclerosis (MS) diagnosis is based on neurologists’ assessment using a combination of tools: MRI, physical and cognitive assessments and patient reported symptoms. It is well accepted that current tools do not paint a pro... ver más

30/09/2019

Healios LLC

71K€

Presupuesto del proyecto: 71K€

Líder del proyecto

HEALIOS LLC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo H2020 notifico la concesión del proyecto el día 2019-09-30

EIC-SMEInst-2018-2020: SME instrument

I+D

Cerrada hace 7 años

0% 70% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

Healios LLC

50.00K€ | Lider

JUAN Y JUAN INDUSTRIAL

1.12M€ | Participante

Proyectos interesantes

BeatsDigTherapeutics

Medical Technol...

Data Science

4M€ Cerrado

DPI2017-86696-R

Medical Technol...

Data Science

218K€ Cerrado

ADVANCE-AD

Medical Technol...

Data Science

3M€ Cerrado

PID2019-108435RB-I00

Medical Technol...

Data Science

214K€ Cerrado

TEC2015-64718-R

Medical Technol...

Data Science

175K€ Cerrado

PID2020-114769RB-I00

Medical Technol...

Data Science

213K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Duración del proyecto: 4 meses Fecha Inicio: 2019-05-06
Fecha Fin: 2019-09-30

Líder del proyecto

HEALIOS LLC No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 71K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto Multiple Sclerosis (MS) diagnosis is based on neurologists’ assessment using a combination of tools: MRI, physical and cognitive assessments and patient reported symptoms. It is well accepted that current tools do not paint a proper picture of the patient illness leading to the need of additional insights into patient symptoms. dreaMS aims to be the 1st digital solution for patient with MS providing digital biomarkers to help with diagnosis, prognosis and treatment choice. The solution supports both patients and providers, allowing for more precise treatment strategies and continuous monitoring, resulting in improved patient outcomes and well-being. Our technology is easy scalable to other diseases treatment (like Alzheimer, schizophrenia, or any neurological illness) The global MS treatment market was valued at $16.13 Billion in 2016, and is expected to reach $27.38 Billion by 2025, driven by the continued uptake of premium products and an increase in treatment rates because of the availability of novel alternatives based on digital solutions. dreaMS will enter to the European digital biomarkers market, which is facing major changes that will reshape the competitive environment for solution vendors and service providers during the coming years. Our key users will be neurologists and MS patients that will use the dreaMS technology. Additionally, because dreaMS benefits among value chain (both users and buyers) we will guarantee a global impact. Phase 1 will center on preparing a feasibility study. This will include the following activities: full identification and characterization of our target market, design of the internationalization and business development strategy, definition of technological needs and product validation, identification and clearance of legal issues and definition of our IPR strategy, and finally, design of the finance strategy and a business plan. We plan to use SMEI-1 to identify interested buyers to take part in demonstrations in SMEI-2.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores